Results of Phase III Bravo trial reinforce unique profile of laquinimod for multiple sclerosis treatment
Primary endpoint of reducing annualized relapse rate was not statistically achieved
02-Aug-2011 -
Teva Pharmaceutical Industries Ltd. and Active Biotech announced initial results from the Phase III BRAVO study, which was designed to evaluate the efficacy, safety and tolerability of oral laquinimod compared to placebo and to provide a benefit-risk assessment comparing oral laquinimod and a ...
multiple sclerosis
phase III studies
TEVA